Last reviewed · How we verify
ACAM2000
At a glance
| Generic name | ACAM2000 |
|---|---|
| Sponsor | Emergent BioSolutions |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site pruritus
- Injection site erythema
- Injection site pain
- Lymph node pain
- Blood and lymphatic system disorders
- Nausea
- Diarrhea
- Lymphadenopathy
- Constipation
- Vomiting
- Malaise
- Fatigue
Key clinical trials
- Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Evaluating the Human Immune Response to the JYNNEOS Vaccine (EARLY_PHASE1)
- MVA Post-Event: Administration Timing and Boost Study (PHASE1,PHASE2)
- Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
- Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia (PHASE3)
- Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder (PHASE4)
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACAM2000 CI brief — competitive landscape report
- ACAM2000 updates RSS · CI watch RSS
- Emergent BioSolutions portfolio CI